Clinical Core
临床核心
基本信息
- 批准号:10229542
- 负责人:
- 金额:$ 73.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-15 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:African AmericanAgeAgingAlzheimer&aposs DiseaseAlzheimer&aposs disease pathologyAlzheimer&aposs disease related dementiaAlzheimer&aposs disease therapeuticAutopsyBiological MarkersBrainClinicClinicalClinical TrialsCognitiveCollaborationsCollectionCommunitiesComplexDataData CollectionData SetDeliriumDevelopmentDiseaseElderlyEnrollmentFosteringFutureGeneticGoalsImageIndividualInfrastructureInjuryInterventionLeadershipMRI ScansMagnetic Resonance ImagingMemoryNational Institute on AgingParticipantPathway interactionsPatient RecruitmentsPatientsPharmacologyPhasePreventionProceduresProtocols documentationRecruitment ActivityRegistriesResearchResearch ActivityResearch InstituteResearch PersonnelRiskSamplingSiteTelephoneTissuesTrainingTraining Supportbasecareerclinical centercohortcooperative studydata resourcedata sharinggenomic datainterestmembermild cognitive impairmentneuroimagingneuropathologynext generationnoveloutreachparticipant retentionpre-clinicalpreservationprogramsranpirnaserecruitrepositoryresilience
项目摘要
PROJECT SUMMARY – CLINICAL CORE
The Exploratory Vanderbilt Alzheimer’s Disease Research Center (VADRC) Clinical Core will support local and
national Alzheimer’s disease research activities. Under the direction of Dr. Paul Newhouse, the Clinical Core
will enhance existing institutional infrastructure to engage and recruit older adults into Alzheimer’s disease and
related dementia research opportunities to support creating a future P30 Outreach and Recruitment Core.
Recruitment activities will build upon the existing 4000+ member Alzheimer’s Disease Research Registry and
focus on recruiting memory clinic patients and community-dwelling older adults interested in biomarker-focused
Alzheimer’s disease research opportunities. A strong emphasis will be placed on partnering with the
Vanderbilt-Meharry Alliance for outreach and engagement in the local African American community with a
focus on enhancing biomarker and autopsy participation. The Clinical Core will be responsible for establishing
and annually following a “proof of concept” cohort of 150 well-characterized participants age 60 and older who
are cognitively unimpaired or meet established criteria for mild cognitive impairment or Alzheimer’s disease.
Leveraging well-established protocols and extensive local infrastructure, we will collect detailed clinical,
cognitive, neuroimaging, genetic, and biospecimen data. These data will support our Center’s thematic
emphasis on prevention targets, large-scale discovery, and pharmacological interventions that collectively
emphasize non-amyloid pathways of injury commonly co-occurring with core Alzheimer’s disease pathology.
The Clinical Core will engage cohort participation in antemortem brain donation assent, and a scalable autopsy
protocol pipeline will be implemented to support a future P30 Neuropathology Core in collaboration with the
Rush Alzheimer’s Disease Research Center. The Clinical Core will support local and national research efforts
in Alzheimer’s disease by fostering collaborations and sharing data locally and nationally. Data and
biospecimens will be collected in a uniform manner according to current best-practices and shared with the
National Alzheimer’s Coordinating Center, the National Centralized Repository for Alzheimer’s Disease and
Related Dementias, and the National Institute on Aging Genetics of Alzheimer’s Disease Storage Site. The
Clinical Core will maximize local research initiatives by distributing clinical, cognitive, neuroimaging, genetic,
and biospecimen data to qualified investigators and maximizing Clinical Core cohort participation in
investigator initiated and multi-site studies. Finally, the Clinical Core will support training the next generation of
Alzheimer’s disease clinicians and investigators by providing participants, data, biospecimens, collaboration,
and leadership opportunities. Our interdisciplinary Clinical Core investigators have demonstrated expertise and
a proven track record in participant recruitment and retention as well as complex protocol implementation.
Thus, the Clinical Core will be a successful focal point of the VADRC in supporting both local and national
Alzheimer’s disease research activities.
项目总结-临床核心
探索性范德比尔特阿尔茨海默病研究中心(VADRC)临床核心将支持当地和
国家阿尔茨海默病研究活动。在Paul纽豪斯博士的指导下,
将加强现有的机构基础设施,以吸引和招募老年人参与阿尔茨海默病,
相关的痴呆症研究机会,以支持创建一个未来的P30推广和招聘核心。
招募活动将建立在现有的4000多名成员阿尔茨海默病研究登记处和
专注于招募记忆诊所患者和社区居住的老年人感兴趣的生物标志物为重点
老年痴呆症的研究机会。将着重强调与
范德比尔特-梅哈里联盟,以推广和参与当地非裔美国人社区,
重点加强生物标志物和尸检参与。临床中心将负责建立
并每年对150名年龄在60岁及以上的特征良好的参与者进行“概念验证”,
认知未受损或符合轻度认知障碍或阿尔茨海默病的既定标准。
利用完善的协议和广泛的本地基础设施,我们将收集详细的临床,
认知、神经成像、遗传和生物样本数据。这些数据将支持我们中心的主题
强调预防目标、大规模发现和药理干预,
强调非淀粉样蛋白损伤途径通常与核心阿尔茨海默病病理学共同发生。
临床核心将参与队列参与死前脑捐赠同意,并进行可扩展的尸检
协议管道将实施,以支持未来的P30神经病理学核心与
拉什阿尔茨海默病研究中心。临床核心将支持当地和国家的研究工作
通过促进合作和分享当地和全国的数据来治疗阿尔茨海默病。数据和
生物标本将根据目前的最佳做法以统一的方式收集,并与
国家阿尔茨海默氏症协调中心,国家阿尔茨海默氏症集中储存库,
相关痴呆症,和国家研究所对老年痴呆症的遗传储存网站。的
临床核心将通过分布临床,认知,神经影像,遗传,
和生物样本数据,并最大限度地提高临床核心队列的参与率,
研究者发起的多中心研究。最后,临床核心将支持培训下一代
阿尔茨海默病临床医生和研究人员通过提供参与者,数据,生物标本,合作,
和领导机会。我们的跨学科临床核心研究人员已经证明了专业知识,
在参与者招募和保留以及复杂的协议执行方面有良好的记录。
因此,临床核心将成为VADRC在支持地方和国家
阿尔茨海默病研究活动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL A. NEWHOUSE其他文献
PAUL A. NEWHOUSE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL A. NEWHOUSE', 18)}}的其他基金
The cholinergic integrity in Down syndrome in association with aging, Alzheimer's disease pathology, and cognition
唐氏综合症的胆碱能完整性与衰老、阿尔茨海默病病理学和认知的关系
- 批准号:
10353561 - 财政年份:2022
- 资助金额:
$ 73.82万 - 项目类别:
Multisensory Processing Across Lifespan and Links to Cognition
整个生命周期的多感官处理及其与认知的联系
- 批准号:
8576040 - 财政年份:2013
- 资助金额:
$ 73.82万 - 项目类别:
Multisensory Processing Across Lifespan and Links to Cognition
整个生命周期的多感官处理及其与认知的联系
- 批准号:
8703646 - 财政年份:2013
- 资助金额:
$ 73.82万 - 项目类别:
ESTROGEN EFFECTS ON CHOLINERGIC FUNCTION IN OLDER WOMEN
雌激素对老年女性胆碱能功能的影响
- 批准号:
8166965 - 财政年份:2010
- 资助金额:
$ 73.82万 - 项目类别:
PHYSICAL ACTIVITY, TESTOSTERONE AND COGNITION IN OLDER MEN
老年男性的体力活动、睾酮和认知
- 批准号:
8166979 - 财政年份:2010
- 资助金额:
$ 73.82万 - 项目类别:
ESTROGEN EFFECTS ON CHOLINERGIC FUNCTION IN OLDER WOMEN
雌激素对老年女性胆碱能功能的影响
- 批准号:
8166991 - 财政年份:2010
- 资助金额:
$ 73.82万 - 项目类别:
A FMRI PILOT STUDY OF ESTROGEN AND CHOLINERGIC SYSTEM IN POST-MENOPAUSE
绝经后雌激素和胆碱能系统的 FMRI 试点研究
- 批准号:
8166967 - 财政年份:2010
- 资助金额:
$ 73.82万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Phenomenon of Stem Cell Aging according to Methylation Estimates of Age After Hematopoietic Stem Cell Transplantation
根据造血干细胞移植后甲基化年龄估算干细胞衰老现象
- 批准号:
23K07844 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Age-dependent Functional Changes in Skeletal Muscle CB1 Receptors by an in Vitro Model of Aging-related Muscle Atrophy
通过衰老相关性肌肉萎缩的体外模型分析骨骼肌 CB1 受体的年龄依赖性功能变化
- 批准号:
22KJ2960 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Joint U.S.-Japan Measures for Aging and Dementia Derived from the Prevention of Age-Related and Noise-induced Hearing Loss
美日针对预防与年龄相关和噪声引起的听力损失而导致的老龄化和痴呆症联合措施
- 批准号:
23KK0156 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Fund for the Promotion of Joint International Research (International Collaborative Research)
The Effects of Muscle Fatigability on Gait Instability in Aging and Age-Related Falls Risk
肌肉疲劳对衰老步态不稳定性和年龄相关跌倒风险的影响
- 批准号:
10677409 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Characterizing gut physiology by age, frailty, and sex: assessing the role of the aging gut in "inflamm-aging"
按年龄、虚弱和性别表征肠道生理学特征:评估衰老肠道在“炎症衰老”中的作用
- 批准号:
497927 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Deciphering the role of osteopontin in the aging eye and age-related macular degeneration
破译骨桥蛋白在眼睛老化和年龄相关性黄斑变性中的作用
- 批准号:
10679287 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Role of AGE/RAGEsignaling as a driver of pathological aging in the brain
AGE/RAGE信号传导作为大脑病理性衰老驱动因素的作用
- 批准号:
10836835 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Elucidation of the protein kinase NLK-mediated aging mechanisms and treatment of age-related diseases
阐明蛋白激酶NLK介导的衰老机制及年龄相关疾病的治疗
- 批准号:
23K06378 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Underlying mechanisms of age-related changes in ingestive behaviors: From the perspective of the aging brain and deterioration of the gustatory system.
与年龄相关的摄入行为变化的潜在机制:从大脑老化和味觉系统退化的角度来看。
- 批准号:
23K10845 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
$ 73.82万 - 项目类别:
Operating Grants














{{item.name}}会员




